Alkem Labs Share Price Target 2026: Brokerages Nuvama and Motilal Oswal have raised target price of Alkem Laboratories, a day after the drug maker announced its Q4 FY26 results. The brokerages cited that the company’s CDMO and medtech businesses will drive India’s future growth.
Brokerage Nuvama has upgraded Alkem Lab’s stock to Buy from Hold with a target price of Rs 6,270 vs Rs 5,800.
Key takeaways from the coverage
– Q4FY26 Margin/PAT miss on elevated R&D, finance and tax costs
– CDMO and MedTech to propel future growth in India
– Tax guidance revision — a relief
– Increase FY27E EPS estimate by 11%
Motilal Oswal on Alkem Labs
The brokerage has maintained Neutral call on the pharma stock with a target price of Rs 5,840 vs Rs 5,540.
Key takeaways from the coverage
– Strong finish; softer road ahead
– Domestic revival and US momentum intact; opex limits the earnings upgrade cycle
– Segmental mix benefit offset by higher operational costs YoY
– International business drives growth; gradual revival in DF raise our earnings estimate by 3%/5% for FY27/FY28
– Expect moderation in the earnings growth trajectory over the next 2 years
– Due to operational costs related to biosimilars for the US market, efforts towards improving growth prospects of the Occlutech business, and a step-up in tax rate from 18% in FY26 to 27-28% in FY27
(Disclaimer: The above article is meant for informational purposes only, and should not be considered as any investment advice. ET NOW DIGITAL suggests its readers/audience to consult their financial advisors before making any money related decisions.)
